4-Chloropyridine Hydrochloride CAS:7379-35-3 – Custom synthesis and contract manufacturing of fine chemicals and pharmaceutical intermediates

4-Chloropyridine Hydrochloride

Synonyms：

4-chloropyridine,hydrochloride

Pyridine, 4-chloro-, hydrochloride

molecular formula: C5H5Cl2N

Molecular weight: 150.00600

Physical Properties:

Appearance and properties: light yellow crystalline powder

Boiling point: 146.9ºC at 760 mmHg

Melting point: 210 °C (subl.)(lit.)

Flash point: 198 °C

Specification:

Items	Standard	Results
Appearance	White or light yellow powder	Conformity
Assay	≥98.0%	99. 10%
Moisture	≤0.5%	0.42%
Melting point	210-220℃	210.5-215.0℃

Application:

4-Chloropyridine is used to synthesize Thrombin inhibitors, compounds that have potent anticoagulant activity. 4-Chloropyridine is also used as a reagent to synthesize Botryllazine A, a pyrazine alkaloid that exhibits cytotoxicity against human tumour cells.

Package and Storage:

1kg/bottle or bag

25kgs/drum or bag

We are professional 4-Chloropyridine Hydrochloride manufacturer and Pyridine, 4-chloro-, hydrochloride supplier in China, We offer quality Pyridine, 4-chloro-, hydrochloride you can fully trust, also we have India factory and producer of Pyridine, 4-chloro-, hydrochloride,Pls send inquiry of Pyridine, 4-chloro-, hydrochloride CAS:7379-35-3 to info@nbinno.com if you have any interests, thank you!

Related News: The jury unanimously ruled in Plexxikon’s favor on all seven questions, including that Novartis has not proved the specification of the patent was full and clear enough to enable a person of “ordinary skill” to make and use the invention.Sodium tetraphenylborate manufacturer “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. 4-Methyl-2-(3,3,3-trifluoro-propyl)-1H-imidazole supplier ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 2-bromotridecane manufacturer Competition is indeed “severe” from local firms, Wang said, but the company is working to add new drugs and indications to the market and is noticing increased volumes from national reimbursement deals.